News | PET Imaging | June 14, 2016

Competition Seeks First PET Tracer for Key Parkinson's Protein

First team to develop viable tracer will receive $2 million prize from The Michael J. Fox Foundation

Michael J. Fox Foundation, MJFF, Parkinson's, PET tracer, competition, SNMMI 2016

June 14, 2016 — The Michael J. Fox Foundation (MJFF) announced a $2 million prize for development of a positron emission tomography (PET) tracer to visualize the protein alpha-synuclein, the priority therapeutic target and biomarker candidate of Parkinson's disease research. The prize aims to motivate the field toward this vital research tool, which would allow for earlier and more precise diagnosis, progression tracking, and more efficient and effective intervention testing.

"The ability to image alpha-synuclein in the brain would be a game-changer for Parkinson's translational research and would rapidly accelerate testing of therapies to slow or stop disease progression," said Jamie Eberling, Ph.D., MJFF director of research programs, who announced the prize at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting.

Academic and industry researchers, MJFF-funded or not, are eligible to apply for the prize. Contestants must provide pre-clinical and clinical data showing selectivity and viability of their alpha-synuclein radiotracer. Importantly, contestants must also agree to make their radiotracer available for use by the Foundation and MJFF awardees through a nonexclusive license or other MJFF-approved mechanism. There is no deadline for submission; the prize will go to the first team that shows compelling evidence.

Alpha-synuclein accumulates in the brains of people with Parkinson's disease, and researchers believe that aggregation is the cause of cell degeneration and death responsible for Parkinson's symptoms and progression. Five therapies that aim to prevent or degrade alpha-synuclein aggregates (called Lewy bodies) are currently in clinical trials, with more poised to enter human testing in the next few years.

However, the lack of an objective biological measure (or biomarker) of Parkinson's slows testing of new treatments. The ability to visualize alpha-synuclein in the brain would allow scientists to confirm diagnosis earlier, and thereby intervene earlier; monitor disease progression; and determine a patient's response to treatment in clinical studies.

MJFF is partnering Prothena Corp. plc, a biotechnology company developing protein immunotherapies for diseases including Parkinson’s, to support complementary work measuring alpha-synuclein in peripheral tissues and fluids.

The Michael J. Fox Foundation has long supported the pursuit of an alpha-synuclein PET tracer — in addition to funding of alpha-synuclein therapies and projects investigating peripheral measures of this key protein. In 2011, with little activity in the field, MJFF established a public-private Alpha-synuclein Imaging Consortium to begin work toward such a tool. If the Foundation consortium is the first to build compelling evidence of a viable, selective tracer, members of the team excluding MJFF staff will be awarded the prize. The Foundation also funds a number of independent studies toward an alpha-synuclein radiotracer.

For more information: www.michaeljfox.org

Related Content

Videos | Radiation Therapy | February 15, 2019
ITN Associate Editor Jeff Zagoudis speaks with Vinai Gondi, M.D., director of research and CNS neuro-oncology at the
Videos | Angiography | February 08, 2019
This is an example of an arterial venous malformation (AVM) in the brain imaged on a...
Medtronic Recalls Synergy Cranial Software and Stealth Station S7 Cranial Software
News | Procedure Navigation Systems | February 05, 2019
Medtronic is recalling the Synergy Cranial Software and StealthStation S7 Cranial Software used with the StealthStation...
ImaginAb Enrolls First Patient in Phase II PET Agent Clinical Trial
News | Radiopharmaceuticals and Tracers | January 30, 2019
ImaginAb Inc. announced the enrollment of the first patient in the Phase II clinical trial of the company’s CD8+ T Cell...
FDA Clears United Imaging Healthcare uExplorer Total-Body Scanner
Technology | PET-CT | January 23, 2019
January 23, 2019 — United Imaging Healthcare (United Imaging) announced U.S.
MIM Software Inc. Receives FDA 510(k) Clearance for Molecular Radiotherapy Dosimetry
Technology | Nuclear Imaging | January 16, 2019
MIM Software Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for molecular radiotherapy...
Machine Learning Uncovers New Insights Into Human Brain Through fMRI
News | Neuro Imaging | January 11, 2019
An interdisciplinary research team led by scientists from the National University of Singapore (NUS) has successfully...
Hypertension With Progressive Cerebral Small Vessel Disease Increases Cognitive Impairment Risk
News | Magnetic Resonance Imaging (MRI) | January 08, 2019
Patients with high blood pressure and progression of periventricular white matter hyperintensities showed signs of...
Artificial Intelligence Pinpoints Nine Different Abnormalities in Head Scans

A brain scan (left) showing an intraparenchymal hemorrhage in left frontal region and a scan (right) of a subarachnoid hemorrhage in the left parietal region. Both conditions were accurately detected by the Qure.ai tool. Image courtesy of Nature Medicine.

News | Artificial Intelligence | January 07, 2019
The rise in the use of computed tomography (CT) scans in U.S. emergency rooms has been a well-documented trend1 in...
First Arterial and Venous Atlas of the Human Brain Released
News | Neuro Imaging | January 02, 2019
January 2, 2019 — Imagine an atlas containing an image bank of the blood vessels of the...